These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 26271532)

  • 1. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
    Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
    Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
    Siderowf A; Concha-Marambio L; Lafontant DE; Farris CM; Ma Y; Urenia PA; Nguyen H; Alcalay RN; Chahine LM; Foroud T; Galasko D; Kieburtz K; Merchant K; Mollenhauer B; Poston KL; Seibyl J; Simuni T; Tanner CM; Weintraub D; Videnovic A; Choi SH; Kurth R; Caspell-Garcia C; Coffey CS; Frasier M; Oliveira LMA; Hutten SJ; Sherer T; Marek K; Soto C;
    Lancet Neurol; 2023 May; 22(5):407-417. PubMed ID: 37059509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning.
    Severson KA; Chahine LM; Smolensky LA; Dhuliawala M; Frasier M; Ng K; Ghosh S; Hu J
    Lancet Digit Health; 2021 Sep; 3(9):e555-e564. PubMed ID: 34334334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit.
    Leger C; Herbert M; DeSouza JFX
    Front Neurol; 2020; 11():364. PubMed ID: 32477243
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.
    Dinov ID; Heavner B; Tang M; Glusman G; Chard K; Darcy M; Madduri R; Pa J; Spino C; Kesselman C; Foster I; Deutsch EW; Price ND; Van Horn JD; Ames J; Clark K; Hood L; Hampstead BM; Dauer W; Toga AW
    PLoS One; 2016; 11(8):e0157077. PubMed ID: 27494614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of Scans Without Evidence of Dopamine Deficit (SWEDD) According to the Olfactory Function.
    Oh YS; Choi JH; Kwon DY
    J Parkinsons Dis; 2016 Oct; 6(4):771-778. PubMed ID: 27567887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.
    Chahine LM; Chin I; Caspell-Garcia C; Standaert DG; Brown E; Smolensky L; Arnedo V; Daeschler D; Riley L; Korell M; Dobkin R; Amondikar N; Gradinscak S; Shoulson I; Dean M; Kwok K; Cannon P; Marek K; Kopil C; Tanner CM; Marras C;
    J Parkinsons Dis; 2020; 10(2):677-691. PubMed ID: 31958097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
    Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
    Prakash N; Caspell-Garcia C; Coffey C; Siderowf A; Tanner CM; Kieburtz K; Mollenhauer B; Galasko D; Merchant K; Foroud T; Chahine LM; Weintraub D; Casaceli C; Dorsey R; Wilson R; Herzog M; Daegele N; Arnedo V; Frasier M; Sherer T; Marek K; Frank S; Jennings D; Simuni T; ; ; ; ;
    Parkinsonism Relat Disord; 2019 May; 62():201-209. PubMed ID: 30738748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study.
    Archer DB; Bricker JT; Chu WT; Burciu RG; McCracken JL; Lai S; Coombes SA; Fang R; Barmpoutis A; Corcos DM; Kurani AS; Mitchell T; Black ML; Herschel E; Simuni T; Parrish TB; Comella C; Xie T; Seppi K; Bohnen NI; Müller ML; Albin RL; Krismer F; Du G; Lewis MM; Huang X; Li H; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Lancet Digit Health; 2019 Sep; 1(5):e222-e231. PubMed ID: 33323270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
    Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
    Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.
    Gwinn K; David KK; Swanson-Fischer C; Albin R; Hillaire-Clarke CS; Sieber BA; Lungu C; Bowman FD; Alcalay RN; Babcock D; Dawson TM; Dewey RB; Foroud T; German D; Huang X; Petyuk V; Potashkin JA; Saunders-Pullman R; Sutherland M; Walt DR; West AB; Zhang J; Chen-Plotkin A; Scherzer CR; Vaillancourt DE; Rosenthal LS
    Biomark Med; 2017 May; 11(6):451-473. PubMed ID: 28644039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japan Parkinson's Progression Markers Initiative (J-PPMI).
    Mukai Y; Murata M
    Nihon Rinsho; 2017 Jan; 75(1):151-155. PubMed ID: 30566310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.